703 611

Cited 0 times in

The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01

DC Field Value Language
dc.contributor.author강석구-
dc.contributor.author김세훈-
dc.contributor.author김의현-
dc.contributor.author윤홍인-
dc.contributor.author장종희-
dc.contributor.author조재호-
dc.date.accessioned2020-02-26T06:29:35Z-
dc.date.available2020-02-26T06:29:35Z-
dc.date.issued2019-
dc.identifier.issn2288-2405-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/175173-
dc.description.abstractBACKGROUND: There was no practical guideline for the management of patients with central nervous system tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has developed the guideline for glioblastoma. Subsequently, the KSNO guideline for World Health Organization (WHO) grade II cerebral glioma in adults is established. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searching PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords regarding diffuse astrocytoma and oligodendroglioma of brain in adults. RESULTS: Whenever radiological feature suggests lower grade glioma, the maximal safe resection if feasible is recommended globally. After molecular and histological examinations, patients with diffuse astrocytoma, isocitrate dehydrogenase (IDH)-wildtype without molecular feature of glioblastoma should be primarily treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy (Level III) while those with molecular feature of glioblastoma should be treated following the protocol for glioblastomas. In terms of patients with diffuse astrocytoma, IDH-mutant and oligodendroglioma (IDH-mutant and 1p19q codeletion), standard brain radiotherapy and adjuvant PCV (procarbazine+lomustine+vincristine) combination chemotherapy should be considered primarily for the high-risk group while observation with regular follow up should be considered for the low-risk group. CONCLUSION: The KSNO's guideline recommends that WHO grade II gliomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors and clinical characteristics of patients.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Brain Tumor Society-
dc.relation.isPartOfBrain Tumor Research and Treatment-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleThe Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurosurgery (신경외과학교실)-
dc.contributor.googleauthorYoung Zoon Kim-
dc.contributor.googleauthorChae-Yong Kim-
dc.contributor.googleauthorChan Woo Wee-
dc.contributor.googleauthorTae Hoon Roh-
dc.contributor.googleauthorJe Beom Hong-
dc.contributor.googleauthorHyuk-Jin Oh-
dc.contributor.googleauthorSeok-Gu Kang-
dc.contributor.googleauthorShin-Hyuk Kang-
dc.contributor.googleauthorDoo-Sik Kong-
dc.contributor.googleauthorSung Hwan Kim-
dc.contributor.googleauthorSe-Hyuk Kim-
dc.contributor.googleauthorSe Hoon Kim-
dc.contributor.googleauthorYu Jung Kim-
dc.contributor.googleauthorEui Hyun Kim-
dc.contributor.googleauthorIn Ah Kim-
dc.contributor.googleauthorHo Sung Kim-
dc.contributor.googleauthorJae-Sung Park-
dc.contributor.googleauthorHyun Jin Park-
dc.contributor.googleauthorSang Woo Song-
dc.contributor.googleauthorKyoung Su Sung-
dc.contributor.googleauthorSeung Ho Yang-
dc.contributor.googleauthorWan-Soo Yoon-
dc.contributor.googleauthorHong In Yoon-
dc.contributor.googleauthorJihae Lee-
dc.contributor.googleauthorSoon-Tae Lee-
dc.contributor.googleauthorSea-Won Lee-
dc.contributor.googleauthorYoun Soo Lee-
dc.contributor.googleauthorJaejoon Lim-
dc.contributor.googleauthorJong Hee Chang-
dc.contributor.googleauthorTae-Young Jung-
dc.contributor.googleauthorHye Lim Jung-
dc.contributor.googleauthorJae Ho Cho-
dc.contributor.googleauthorSeung Hong Choi-
dc.contributor.googleauthorHyoung Soo Choi-
dc.contributor.googleauthorDo Hoon Lim-
dc.contributor.googleauthorDong-Sup Chung-
dc.identifier.doi10.14791/btrt.2019.7.e43-
dc.contributor.localIdA00036-
dc.contributor.localIdA00610-
dc.contributor.localIdA00837-
dc.contributor.localIdA04777-
dc.contributor.localIdA03470-
dc.contributor.localIdA03901-
dc.relation.journalcodeJ00398-
dc.identifier.eissn2288-2413-
dc.identifier.pmid31686437-
dc.subject.keywordGrade II Gliomas-
dc.subject.keywordGuideline-
dc.subject.keywordKorean Society for Neuro-Oncology-
dc.subject.keywordPractice-
dc.contributor.alternativeNameKang, Seok Gu-
dc.contributor.affiliatedAuthor강석구-
dc.contributor.affiliatedAuthor김세훈-
dc.contributor.affiliatedAuthor김의현-
dc.contributor.affiliatedAuthor윤홍인-
dc.contributor.affiliatedAuthor장종희-
dc.contributor.affiliatedAuthor조재호-
dc.citation.volume7-
dc.citation.number2-
dc.citation.startPage74-
dc.citation.endPage84-
dc.identifier.bibliographicCitationBrain Tumor Research and Treatment, Vol.7(2) : 74-84, 2019-
dc.identifier.rimsid64865-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.